期刊文献+
共找到4,128篇文章
< 1 2 207 >
每页显示 20 50 100
Experimental study on effect of recombinant human growth hormone combined with chemotherapy on stomach neoplasms implanted in nude mice 被引量:1
1
作者 Fangfang Shi Suyi Li 《The Chinese-German Journal of Clinical Oncology》 CAS 2007年第1期27-31,共5页
Objective: To investigate the effect of different doses of recombined growth hormone (rhGH) on stomach neo- plasms implanted in nude mice, and its efficacy in combining with chemotherapy (flurouracil, 5-FU). Methods: ... Objective: To investigate the effect of different doses of recombined growth hormone (rhGH) on stomach neo- plasms implanted in nude mice, and its efficacy in combining with chemotherapy (flurouracil, 5-FU). Methods: Human stom- ach neoplasms model was established in nude mice. The nude mice were divided into control group, moderate-dose of rhGH group, low-dose rhGH group, 5-FU group, moderate-dose rhGH/5-FU group, and low-dose rhGH/5-FU group. The results of each group were observed after ten days. Results: After therapy, the body mass of rhGH groups was significantly increased compared with control group (P<0.05), the body mass of rhGH/5-FU groups was significantly increased compared with 5-FU group (P<0.05), but it was no significant difference between rhGH/5-FU groups and control group (P>0.05). The average tumor mass and volume of rhGH groups were not significantly increased compared with control group (P>0.05), but they were significantly reduced in 5-FU group and rhGH/5-FU groups (P<0.05). They were no significant difference between rhGH/5- FU groups and 5-FU group (P>0.05). After treatment, the percentages of S, G0/G1 and G2/M phases and proliferation index (PI) were not significantly changed in rhGH groups compared with control group (P>0.05), and the same with rhGH/5-FU groups compared with 5-FU group (P>0.05). The difference caused by dose of rhGH was not significant. Conclusion: rhGH enhances body mass, does not stimulate tumor growth, and has no adverse effects on tumor bearing nude mice. Combined with flurouracil, rhGH does not influence the efficacy of chemotherapy, and has no effect on tumor cell cycle kinetics. 展开更多
关键词 重组人生长激素 联合化疗 胃肿瘤移植 裸鼠 实验研究
下载PDF
Current gene therapy for stomach carcinoma 被引量:16
2
作者 Chang-Tai Xu~1 Lian-Tian Huang~1 Bo-Rong Pan~2 1 Editorial Department,the Journal of Fourth Military Medical University2 Oncology Center,Xijing Hospital,Fourth Military Medical University,169 Changle Xilu,Xi’an 710032,Shaanxi Province,China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第6期752-759,共8页
Gastric cancer is common in China [1-42],and its early diagnosis and treatment in advanced stage are difficult [31-50].In recent years ,gene study in cancer is a hotspot ,and great progress has been achieved [41-80] .... Gastric cancer is common in China [1-42],and its early diagnosis and treatment in advanced stage are difficult [31-50].In recent years ,gene study in cancer is a hotspot ,and great progress has been achieved [41-80] .Cancer gene therapy has shifted from the imagination into the laboratory and clinical trials. 展开更多
关键词 stomach neoplasms/therapy gene therapy carcinoembryonic antigen/genetics NITRIC-OXIDE synthase/genetics review literature
下载PDF
Intensify standardized therapy for esophageal and stomach cancer in tumor hospitals 被引量:9
3
作者 Shi Jie Wang Deng Gui Wen +2 位作者 Jing Zhang Xin Man Hui Liu Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第1期80-82,共3页
INTRODUCTIONCancer treatment situation in tumor hospitals inChina has its own unique characteristics which arenot found in other parts of the world. Because ofthe huge population and high incidence rates ofesophageal ... INTRODUCTIONCancer treatment situation in tumor hospitals inChina has its own unique characteristics which arenot found in other parts of the world. Because ofthe huge population and high incidence rates ofesophageal and stomach cancer[1-5], the number ofcancer patients waiting for admission isinconceivably large. 展开更多
关键词 ESOPHAGEAL neoplasms/ therapy stomach neoplasms/therapy endoscopy digestive system chemotherapy ADJUVANT radiotherapy surgery OPERATIVE
下载PDF
Immunotherapy for recurrent hepatocellular carcinoma
4
作者 Ahan Bhatt Jennifer Wu 《World Journal of Gastroenterology》 SCIE CAS 2023年第15期2261-2271,共11页
Hepatocellular carcinoma(HCC)is presented frequently in late stages that are not amenable for curative treatment.Even for patients who can undergo resection for curative treatment of HCC,up to 50%recur.For patients wh... Hepatocellular carcinoma(HCC)is presented frequently in late stages that are not amenable for curative treatment.Even for patients who can undergo resection for curative treatment of HCC,up to 50%recur.For patients who were not exposed to systemic therapy prior to recurrence,recurrence frequently cannot be subjected to curative therapy or local treatments.Such patients have several options of immunotherapy(IO).This includes programmed cell death protein 1(PD-1)and cytotoxic T-lymphocyte associated protein 4 treatment,combination of PD-1 and vascular endothelial growth factor inhibitor or single agent PD-1 therapy when all other options are deemed inappropriate.There are also investigational therapies in this area that explore either PD-1 and tyrosine kinase inhibitors or a novel agent in addition to PD-1 with vascular endothelial growth factor inhibitors.This minireview explored IO options for patients with recurrent HCC who were not exposed to systemic therapy at the initial diagnosis.We also discussed potential IO options for patients with recurrent HCC who were exposed to first-line therapy with curative intent at diagnosis. 展开更多
关键词 Liver neoplasms Immune checkpoint blockade Combination drug therapy PD-1-PD-L1 blockade CTLA-4 inhibitor
下载PDF
肝癌靶向联合免疫治疗耐药后的二线治疗方案研究进展 被引量:1
5
作者 张天奇 曹钰哲 +1 位作者 左孟轩 顾仰葵 《临床肝胆病杂志》 CAS 北大核心 2024年第2期386-390,共5页
近年来,靶向和免疫单药及联合治疗晚期肝癌的临床研究为一线用药方案选择提供了丰富的疗效与安全性证据。然而,对于肝癌二线治疗方案的选择,目前各项临床指南尚无统一意见,原因在于现有循证医学证据局限于索拉非尼失败后的选择,而对于... 近年来,靶向和免疫单药及联合治疗晚期肝癌的临床研究为一线用药方案选择提供了丰富的疗效与安全性证据。然而,对于肝癌二线治疗方案的选择,目前各项临床指南尚无统一意见,原因在于现有循证医学证据局限于索拉非尼失败后的选择,而对于新的一线方案,如靶向免疫联合治疗肝癌耐药后的二线治疗方案,依然缺乏高证据等级的临床试验结论。本文回顾了目前临床试验研究结果,根据药物作用的不同机制,对靶向免疫一线治疗耐药后肝癌二线治疗方案的研究进行了归纳,并系统总结近年研究进展。对于一线靶免联合治疗耐药的肝癌患者,靶向联合治疗、免疫双抗治疗均有望提高疗效、改善生存,未来还需更多前瞻性临床研究数据,为靶免联合治疗耐药的肝癌患者提供有效、安全的治疗方案。 展开更多
关键词 肝细胞 药物疗法 抗药性 肿瘤
下载PDF
垂体催乳素瘤的临床特点及诊治要点更新--基于《2022版ICCE/AME垂体催乳素瘤临床实践共识》解读 被引量:1
6
作者 谭惠文 李丹婷 余叶蓉 《中国全科医学》 北大核心 2024年第6期650-655,共6页
垂体催乳素瘤是一种由垂体催乳素细胞瘤过量合成和分泌催乳素引起的神经内分泌疾病,垂体催乳素瘤的规范化诊疗对于恢复并维持患者的正常垂体功能并提高其生活质量具有重要意义。2022年1月,《欧洲内分泌杂志》发布了国际临床内分泌学分会... 垂体催乳素瘤是一种由垂体催乳素细胞瘤过量合成和分泌催乳素引起的神经内分泌疾病,垂体催乳素瘤的规范化诊疗对于恢复并维持患者的正常垂体功能并提高其生活质量具有重要意义。2022年1月,《欧洲内分泌杂志》发布了国际临床内分泌学分会(ICCE)与意大利临床内分泌学家协会(AME)关于垂体催乳素瘤的临床实践最新共识申明——《2022版ICCE/AME垂体催乳素瘤临床实践共识》(简称2022版ICCE/AME新共识)。2022版ICCE/AME新共识立足最新循证医学证据,对于垂体催乳素瘤的临床诊治问题进行系统性阐述、分析和建议。本文围绕2022版ICCE/AME新共识关于垂体催乳素瘤的诊断、治疗、特殊人群、多巴胺激动剂抵抗及侵袭性疾病等诊治要点更新进行解读,希望有助于全科医生及内分泌专科医生对于垂体催乳素瘤的认识,为其临床实践的规范化诊疗提供参考。 展开更多
关键词 催乳素瘤 垂体肿瘤 高催乳素血症 指南 催乳素 多巴胺激动剂 药物治疗
下载PDF
免疫细胞及炎症因子对晚期肺癌一线化疗效果的预测价值
7
作者 卢超 胡志清 吴亚斌 《医学临床研究》 CAS 2024年第5期750-753,共4页
【目的】探讨T淋巴细胞亚群、肿瘤浸润T淋巴细胞(Tils)及炎症因子对晚期肺癌一线化疗效果的预测价值。【方法】检测98例首诊TNM分期为Ⅲ/Ⅳ期的非小细胞肺腺癌患者的血清白细胞介素1α(IL-1α)、IL-6、IL-17、γ-干扰素(INF-γ)水平及T... 【目的】探讨T淋巴细胞亚群、肿瘤浸润T淋巴细胞(Tils)及炎症因子对晚期肺癌一线化疗效果的预测价值。【方法】检测98例首诊TNM分期为Ⅲ/Ⅳ期的非小细胞肺腺癌患者的血清白细胞介素1α(IL-1α)、IL-6、IL-17、γ-干扰素(INF-γ)水平及T淋巴细胞亚群CD4^(+)T、CD8^(+)T、调节性T细胞、CD57^(+)细胞、Granzyme B^(+)细胞、CD45RO^(+)细胞比例;所有患者均接受紫杉醇注射液+顺铂化疗,治疗4个周期后评定疗效,并据此分为有效组和无效组,分析化疗无效的影响因素及预测疗效的有效标志物。【结果】化疗后,98例患者中69例化疗有效,29例无效。无效组患者淋巴结转移占比及调节性T细胞、IL-1α表达水平均高于有效组(P<0.05),CD57^(+)细胞、CD45RO^(+)细胞比例均低于有效组(P<0.05)。多因素逐步Logistic回归分析结果显示,调节性T细胞、IL-1α水平高是肺癌患者化疗无效的危险因素(P<0.05),CD57^(+)细胞、CD45RO^(+)细胞比例高是保护因素(P<0.05)。受试者工作特征(ROC)曲线分析显示,调节性T细胞、CD57^(+)细胞、CD45RO^(+)细胞、IL-1α水平预测化疗效果的灵敏度分别为82.76%、86.21%、89.66%、93.10%,四者联合的灵敏度、特异度和曲线下面积(AUC)分别为82.76%、97.10%、0.957。【结论】T淋巴细胞亚群、Tils及炎症因子水平与晚期肺癌治疗效果密切相关,其可作为预测疗效的敏感指标。 展开更多
关键词 肺肿瘤 T淋巴细胞亚群 炎症趋化因子类/血液 药物疗法 治疗结果
下载PDF
GLI1表达与肿瘤免疫浸润及胃癌临床预后的关系
8
作者 朱文帅 孙菁果 +3 位作者 鲁艺 栾慕华 马晓丽 郏雁飞 《中国现代普通外科进展》 CAS 2024年第1期8-13,共6页
目的:探讨胃癌中胶质瘤相关癌基因1(GLI1)的表达与免疫浸润相关性,及其与临床预后的相关性。研究GLI1的表达对胃癌化疗药物耐药性的影响。方法:运用TCGA数据库分析GLI1在胃癌和正常组织中的表达差异,分析胃癌患者临床特征和GLI1基因表... 目的:探讨胃癌中胶质瘤相关癌基因1(GLI1)的表达与免疫浸润相关性,及其与临床预后的相关性。研究GLI1的表达对胃癌化疗药物耐药性的影响。方法:运用TCGA数据库分析GLI1在胃癌和正常组织中的表达差异,分析胃癌患者临床特征和GLI1基因表达水平对患者预后的影响;分析胃癌组织中GLI1基因表达与肿瘤免疫细胞浸润的相关性,探究其对化疗药物及靶向药物耐药性的影响。收集临床标本,分析GLI1在胃癌和癌旁组织中的表达差异。结果:胃癌组织中GLI1高表达是正常组织的1.7倍,其高表达患者总生存期、无病生存期较低表达患者更短(P<0.05)。胃癌组织中GLI1的高表达组间质评分、免疫评分、免疫浸润细胞丰度更高,GLI1高表达对药物敏感性降低并且和免疫检查点标志物PDCD1表达呈正相关(P<0.05)。GLI1在低分化胃癌患者中表达明显升高(P<0.05)。结论:GLI1表达与胃癌患者预后及免疫浸润相关,并且其可能通过调节化疗耐药而导致患者的不良预后,可能是胃癌潜在的治疗靶点和分子标志物。 展开更多
关键词 胶质瘤相关癌基因1 胃肿瘤 免疫浸润 预后 耐药性
下载PDF
滋肾润肺方辅助化疗治疗中晚期肺癌气阴两虚证患者的临床疗效
9
作者 徐华智 李宁 马一杰 《医学临床研究》 CAS 2024年第5期718-721,共4页
【目的】探讨滋肾润肺方联合化疗治疗中晚期肺癌气阴两虚证患者的疗效。【方法】两院收治的80例中晚期肺癌气阴两虚证患者,随机分为化疗组与联合组,每组40例。化疗组采用常规肺癌化疗方案,联合组在此基础上同时给予滋肾润肺方口服。比... 【目的】探讨滋肾润肺方联合化疗治疗中晚期肺癌气阴两虚证患者的疗效。【方法】两院收治的80例中晚期肺癌气阴两虚证患者,随机分为化疗组与联合组,每组40例。化疗组采用常规肺癌化疗方案,联合组在此基础上同时给予滋肾润肺方口服。比较两组患者的疗效、疾病进展时间(TTP)、1年存活率、1年无进展生存(PFS)率,治疗前后中医症状积分、卡氏评分(KPS)改善情况,骨髓抑制发生情况。【结果】联合组治疗总有效率(RR)为37.5%(15/40)、疾病控制率(DCR)为82.5%(33/40),化疗组RR为27.5%(11/40)、DCR为70.0%(28/40),两组比较差异均无统计学意义(P>0.05)。化疗组TTP为6.5(4.2~8.4)个月,1年存活率为30.0%(12/40),1年PFS率为85.0%(34/40);联合组TTP为7.2(5.5~9.3)个月,1年存活率35.0%(14/40),1年PFS率为87.5%(35/40),两组比较差异均无统计学意义(P>0.05)。与治疗前比较,两组治疗后中医症状积分均明显降低,且观察组各项指标下降更显著(P<0.05)。治疗后,联合组KPS评分稳定率为90.00%(36/40),明显高于化疗组的70.00%(28/40)(P<0.05)。联合组骨髓抑制的总发生率为17.5%(7/40),低于化疗组的42.5%(17/40)(P<0.05)。【结论】滋肾润肺方联合化疗可有效改善患者的生活质量,且能降低骨髓抑制的发生率。 展开更多
关键词 肺肿瘤/中西医结合疗法 药物疗法 治疗结果
下载PDF
基于妇科肿瘤耐药治疗中工程化外泌体的应用研究进展
10
作者 郭鑫 张建楠 +2 位作者 郭楠 宁文婷 尚海霞 《国际妇产科学杂志》 CAS 2024年第1期42-46,共5页
妇科恶性肿瘤严重威胁着女性健康,在女性各类疾病中其发病率和死亡率均位居前列,关键原因在于传统化疗对复发、耐药患者的疗效欠佳。近年来,探讨肿瘤细胞化疗的耐药机制,开发新型药物逆转耐药已成为妇科肿瘤研究者关注的热点。外泌体(ex... 妇科恶性肿瘤严重威胁着女性健康,在女性各类疾病中其发病率和死亡率均位居前列,关键原因在于传统化疗对复发、耐药患者的疗效欠佳。近年来,探讨肿瘤细胞化疗的耐药机制,开发新型药物逆转耐药已成为妇科肿瘤研究者关注的热点。外泌体(exosome)是一种来源于细胞内溶酶体微粒内陷的多囊泡体,具有低免疫原性、先天靶向性及获得靶向性和高传递效率等生物学特性。因此,外泌体可作为一种理想的、天然的纳米递送药物载体,不仅可以降低肿瘤细胞对化疗药物的耐药性,提高药物治疗效果,还可以减少化疗药物对全身的毒副反应。本文就外泌体作为妇科肿瘤耐药治疗中药物载体的研究进展进行综述,以期对妇科肿瘤的临床治疗提供帮助。 展开更多
关键词 外泌体 生殖器肿瘤 女(雌)性 抗药性 肿瘤 药物载体 分子靶向治疗
下载PDF
Advances in the study of gastric organoids as disease models
11
作者 Yi-Yang Liu De-Kun Wu +2 位作者 Ji-Bing Chen You-Ming Tang Feng Jiang 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第5期1725-1736,共12页
Gastric organoids are models created in the laboratory using stem cells and sophisticated three-dimensional cell culture techniques.These models have shown great promise in providing valuable insights into gastric phy... Gastric organoids are models created in the laboratory using stem cells and sophisticated three-dimensional cell culture techniques.These models have shown great promise in providing valuable insights into gastric physiology and advanced disease research.This review comprehensively summarizes and analyzes the research advances in culture methods and techniques for adult stem cells and induced pluripotent stem cell-derived organoids,and patient-derived organoids.The potential value of gastric organoids in studying the pathogenesis of stomach-related diseases and facilitating drug screening is initially discussed.The construction of gastric organoids involves several key steps,including cell extraction and culture,three-dimensional structure formation,and functional expression.Simulating the structure and function of the human stomach by disease modeling with gastric organoids provides a platform to study the mechanism of gastric cancer induction by Helicobacter pylori.In addition,in drug screening and development,gastric organoids can be used as a key tool to evaluate drug efficacy and toxicity in preclinical trials.They can also be used for precision medicine according to the specific conditions of patients with gastric cancer,to assess drug resistance,and to predict the possibility of adverse reactions.However,despite the impressive progress in the field of gastric organoids,there are still many unknowns that need to be addressed,especially in the field of regenerative medicine.Meanwhile,the reproducibility and consistency of organoid cultures are major challenges that must be overcome.These challenges have had a significant impact on the development of gastric organoids.Nonetheless,as technology continues to advance,we can foresee more comprehensive research in the construction of gastric organoids.Such research will provide better solutions for the treatment of stomach-related diseases and personalized medicine. 展开更多
关键词 ORGANOIDS stomach neoplasms Helicobacter pylori drug evaluation PRECLINICAL PRECISION
下载PDF
抗体药物偶联物在人表皮生长因子受体2低表达胃癌中的应用研究进展
12
作者 康殷楠 石嘉琪 +4 位作者 王俊科 李斌 李初谊 马俊 于晓辉 《中国全科医学》 CAS 北大核心 2024年第18期2287-2294,共8页
胃癌(GC)是极具异质性和侵袭性的消化系统恶性肿瘤之一,传统化疗药物及曲妥珠单抗等人表皮生长因子受体2(HER2)靶向药物在GC的治疗过程中仍然存在耐药性发生率高、毒副作用大、患者耐受差等缺点。因此,研发更为有效的抗GC药物势在必行... 胃癌(GC)是极具异质性和侵袭性的消化系统恶性肿瘤之一,传统化疗药物及曲妥珠单抗等人表皮生长因子受体2(HER2)靶向药物在GC的治疗过程中仍然存在耐药性发生率高、毒副作用大、患者耐受差等缺点。因此,研发更为有效的抗GC药物势在必行。目前针对HER2的新型靶向药层出不穷,但在某些情况下无效或产生耐药,这与HER2在某些GC细胞中低表达有关,HER2低表达(HER2 IHC1+或IHC2+/ISH-)约占全部类型的40%~60%,但在临床实践中,这类患者仍被报告为HER2阴性GC。因此准确检测HER2表达状态对于确定可能受益于曲妥珠单抗治疗的患者至关重要。抗体药物偶联物(ADC)的出现为HER2阳性GC提供了新的治疗选择,凭借其精准高效的抗肿瘤作用,有望在未来替代传统GC化学疗法。近期有研究发现ADC可能在HER2低表达GC中具有潜在抗肿瘤活性,相关临床研究正在评估其在HER2低表达GC治疗中的有效性和安全性。本文就靶向治疗时代ADC在HER2低表达GC患者中的应用和最新研究进展作一综述,并讨论HER2靶向ADC在应用和研发过程中面临的挑战。 展开更多
关键词 胃肿瘤 胃癌 人表皮生长因子受体2 HER2低表达胃癌 抗体药物偶联物 分子靶向治疗 综述
下载PDF
PARP抑制剂在上皮性卵巢癌中的耐药机制及解决策略
13
作者 张文洋 汪希鹏 《国际妇产科学杂志》 CAS 2024年第1期52-59,共8页
上皮性卵巢癌(epithelial ovarian cancer,EOC)的致死率在女性生殖系统恶性肿瘤中居首位。EOC的传统治疗方案是肿瘤细胞减灭术联合铂类药物为基础的化疗,但2年内仍有约70%的患者复发或耐药。多腺苷二磷酸核糖聚合酶[poly(ADP-ribose)pol... 上皮性卵巢癌(epithelial ovarian cancer,EOC)的致死率在女性生殖系统恶性肿瘤中居首位。EOC的传统治疗方案是肿瘤细胞减灭术联合铂类药物为基础的化疗,但2年内仍有约70%的患者复发或耐药。多腺苷二磷酸核糖聚合酶[poly(ADP-ribose)polymerase,PARP]抑制剂通过对乳腺癌相关基因(breast cancer-related gene,BRCA)突变的肿瘤细胞发挥合成致死效应,为EOC提供了全新的治疗模式。PARP抑制剂为EOC靶向维持治疗带来重大突破,然而仍有患者在治疗中逐步耐药,主要的耐药机制包括同源重组修复途径恢复、药物靶点变化和致死性DNA损伤减少,目前的解决策略包括PARP抑制剂联合DNA损伤修复抑制剂、联合抑制同源重组修复通路的药物、联合传统抗癌方案、联合P-糖蛋白(P-glucoprotein,P-gp)抑制剂以及更换其他类型的PARP抑制剂。 展开更多
关键词 多(ADP核糖)聚合酶抑制剂 卵巢肿瘤 肿瘤 腺和上皮 同源重组 基因 BRCA1 基因 BRCA2 药物疗法
下载PDF
多发性骨髓瘤耐药机制和分子靶向治疗新进展——第20届国际骨髓瘤学会年会研究热点报道
14
作者 马静远 郝牧 《转化医学杂志》 2024年第2期292-295,共4页
多发性骨髓瘤(MM)是一种血液恶性肿瘤,其特征为恶性浆细胞的克隆性增殖。蛋白酶体抑制剂、免疫调节药物以及自体造血干细胞移植治疗明显改善了MM患者的生活质量和生存状况,然而几乎所有患者都将产生耐药导致疾病复发难治,预后较差。因此... 多发性骨髓瘤(MM)是一种血液恶性肿瘤,其特征为恶性浆细胞的克隆性增殖。蛋白酶体抑制剂、免疫调节药物以及自体造血干细胞移植治疗明显改善了MM患者的生活质量和生存状况,然而几乎所有患者都将产生耐药导致疾病复发难治,预后较差。因此,探究MM患者耐药性产生的分子机制,寻找新的治疗靶点并开发新的靶向治疗策略尤为重要。现对MM耐药机制和分子靶向治疗研究的最新进展进行综述。 展开更多
关键词 多发性骨髓瘤 抗药性 肿瘤 分子靶向治疗 综述 蛋白酶体抑制剂 免疫调节药物 维奈克拉 嵌合抗原受体
下载PDF
Hippo及Notch信号通路在眼睑基底细胞癌中的研究进展
15
作者 于珞涵 刘龙飞 李超鹏 《转化医学杂志》 2024年第1期141-146,共6页
眼睑基底细胞癌(BCC)是眼睑恶性肿瘤中最常见的类型。手术切除是治疗眼睑BCC的公认金标准,但对于局部晚期或转移性BCC,较大的手术风险和不良预后是困扰医患的最大问题,因此有必要探索新治疗方案。目前靶向治疗具有良好前景,但现有的靶... 眼睑基底细胞癌(BCC)是眼睑恶性肿瘤中最常见的类型。手术切除是治疗眼睑BCC的公认金标准,但对于局部晚期或转移性BCC,较大的手术风险和不良预后是困扰医患的最大问题,因此有必要探索新治疗方案。目前靶向治疗具有良好前景,但现有的靶向药物(Hedgehog信号通路抑制剂)面临难以完全清除肿瘤、毒性作用严重以及耐药的发生问题。鉴于以上情况,开发新的靶向药物对治疗该病具有重要意义。Hippo信号通路和Notch信号通路在眼睑BCC的发生和发展中起着重要作用,可能成为治疗的新靶点。因此,本文综述了Hippo信号通路和Notch信号通路在眼睑BCC中的研究进展,旨在为眼睑BCC的靶向治疗提供新的思路。 展开更多
关键词 眼睑 肿瘤 基底细胞 Hippo信号通路 NOTCH信号通路 靶向治疗 抗药性 肿瘤 YAP/TAZ 综述
下载PDF
A clinical and long-term follow-up study of perioperative sequential triple therapy for gastric cancer 被引量:18
16
作者 Zou SC Qiu HS +1 位作者 Zhang CW Tao HQ 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第2期284-286,共3页
INTRODUCTIONAlthough the long-term postoperative survival rateof gastric cancer(GC) patients has been improvedsignificantly since the local dissection of lymph nodewas widely used in China,yet the low curativeresectio... INTRODUCTIONAlthough the long-term postoperative survival rateof gastric cancer(GC) patients has been improvedsignificantly since the local dissection of lymph nodewas widely used in China,yet the low curativeresection rate and the high recurrence rate fromperitoneal and hepatic metastases hinder it fromfurther improvement.To alter the currentunsatisfactory status of GC treatment,a 展开更多
关键词 stomach neoplasms/surgery stomach neoplasms/drug therapy INTRA-ARTERIAL CHEMOtherapy intra-peritoneal CHEMOtherapy CURATIVE resection survival rate
下载PDF
A study of preoperative methionine-depleting parenteral nutrition plus chemotherapy in gastric cancer patients 被引量:22
17
作者 Cao WX Cheng QM +3 位作者 Fei XF Li SF Yin HR Lin YZ 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第2期255-258,共4页
AIM To investigate the interference ofmethionine.free parenteral nutrition plus 5-Fu(-MetTPN+5-Fu)in gastric cancer cell kineticsand the side effects of the regimen.METHODS Fifteen patients with advancedgastric canc... AIM To investigate the interference ofmethionine.free parenteral nutrition plus 5-Fu(-MetTPN+5-Fu)in gastric cancer cell kineticsand the side effects of the regimen.METHODS Fifteen patients with advancedgastric cancer were randomly divided into twogroups,7 patients were given preoperatively aseven-day course of standard parenteralnutrition in combination with a five-day courseof chemotherapy(sTPN+5-Fu),while the other8 patients were given methionine-deprivedparenteral nutrition and 5-Fu(-MetTPN+5-Fu).Cell cycles of gastric cancer and normal mucosawere studied by flow cytometry(FCM).Bloodsamples were taken to measure the serumprotein,methionine(Met)and cysteine(Cys)levels,and liver and kidney functions.RESULTS As compared with the resultsobtained before the treatment,the percentage ofG<sub>0</sub>/G<sub>1</sub> tumor cells increased and that of S phasedecreased in the-MetTPN+5-Fu group,while thecontrary was observed in the sTPN+5-Fu group.Except that the ALT,AST and AKP levels wereslightly increased in a few cases receiving-MetTPN+5-Fu,all the other biochemicalparameters were within normal limits.Serum Cys level decreased slightly after the treatmentin both groups.Serum Met level of patientsreceiving sTPN+5-Fu was somewhat higher aftertreatment than that before treatment;however,no significant change occurred in the -MetTPN+5-Fu group,nor operative complications in bothgroups.CONCLUSION -MetTPN+5-Fu exerted asuppressive effect on cancer cell proliferation,probably through a double mechanism ofcreating a state of'Met starvation'adverse tothe tumor cell cycle,and by allowing 5-Fu to killspecifically cells in S phase.Preoperative short-term administration of -MetTPN+5-Fu had littleundesirable effect on host metabolism. 展开更多
关键词 stomach neoplasms/drug therapy METHIONINE PARENTERAL NUTRITION
下载PDF
Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas 被引量:24
18
作者 Yin F Shi YQ +3 位作者 Zhao WP Xiao B Miao JY Fan DM 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第5期664-670,共7页
AIM To observe the drug sensitizing effect andrelated mechanisms of fas gene transduction onhuman drug-resistant gastric cancer cellSGC7901/VCR(resistant to Vincristine).METHODS The cell cycle alteration wasobserved b... AIM To observe the drug sensitizing effect andrelated mechanisms of fas gene transduction onhuman drug-resistant gastric cancer cellSGC7901/VCR(resistant to Vincristine).METHODS The cell cycle alteration wasobserved by FACS.The sensitivity of gastriccancer cells to apoptosis was determined by invitro apoptosis assay.The drug sensitization ofcells to several anti-tumor drugs was observedby MTT assay.Immunochemical method wasused to show expression of P-gp and Topo Ⅱ ingastric cancer cells.RESULTS Comparing to SGC7901 and pBK-SGC7901/VCR,fas-SGC7901/VCR showeddecreasing G2 cells and increasing S cells,theG2 phase fraction of pBK-SGC7901/VCR wasabout 3.0 times that of fas-SGC7901/VCR,but Sphase fraction of fas-SGC7901/VCR was about1.9 times that of pBK-SGC7901/VCR,indicatingS phase arrest of fas-SGC7901/VCR.FACS alsosuggested apoptosis of fas-SGC7901/VCR,fas-SGC7901/VCR was more sensitive to apoptosisinducing agent VM-26 than pBK-SGC7901/VCR.MTT assay showed increased sensitization offas-SGC7901/VCR to DDP,MMC and 5-FU,butsame sensitization to VCR according to pBK-SGC7901/VCR.SGC7901,pBK-SGC7901/ VCRand fas-SGC7901/VCR had positively stainedTopo Ⅱ equally.P-gp staining in pBK- SGC7901/VCR was stronger than in SG07901,but there was little staining of P-gp in fas.SGC7901/VCR.CONCLUSION fas gene transduction couldreverse the MDR of human drug-resistant gastriccancer cell SGC7901/VCR to a degree,possiblybecause of higher sensitization to apoptosis anddecreased expression of P-gp. 展开更多
关键词 FAS GENE stomach neoplasms apoptosis drug resistance multiple ANTINEOPLASTIC agents immunocytochemistry/methods GENE TRANSDUCTION
下载PDF
The value of postoperative hepatic regional chemotherapy in prevention of recurrence after radical resection of primary liver cancer 被引量:19
19
作者 Wu ZQ Fan J +2 位作者 Qiu SJ Zhou J Tang ZY 《World Journal of Gastroenterology》 SCIE CAS CSCD 2000年第1期131-133,共3页
INTRODUCTIONIn China,primary liver cancer (PLC) ranks secondin cancer mortality since the 1990s.In the field ofPLC treatment,surgical resection remains the best,which includes large PLC resection,small PLCresection,re... INTRODUCTIONIn China,primary liver cancer (PLC) ranks secondin cancer mortality since the 1990s.In the field ofPLC treatment,surgical resection remains the best,which includes large PLC resection,small PLCresection,re-resection of subclinical recurrence,aswell as cytoreduction and sequential resection forunresectable PLC.However,recurrence 展开更多
关键词 SUBJECT headings liver neoplasms/drug therapy neoplasm recurrence/prevention and control regional chemotherapy
下载PDF
Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs 被引量:23
20
作者 XIAO Bing, SHI Yong Quan, ZHAO Yan Qiu, YOU Han, WANG Zuo You, LIU Xian Ling, YIN Fang, QIAO Tai Dong and FAN Dai Ming 《World Journal of Gastroenterology》 SCIE CAS CSCD 1998年第5期58-62,共5页
INTRODUCTIONChemotherapyisoneofthemajormethodsintumortreatment,butitoftendoesnotworkduetomultidrugresistance... INTRODUCTIONChemotherapyisoneofthemajormethodsintumortreatment,butitoftendoesnotworkduetomultidrugresistance(MDR).Recentstudi... 展开更多
关键词 stomach neoplasms FAS GENE Bcl 2 GENE ANTISENSE nucleic acid drug resistance multiple GENE TRANSDUCTION apoptosis
下载PDF
上一页 1 2 207 下一页 到第
使用帮助 返回顶部